International Flavors & Fragrances Free cash flow decreased by 29.2% to $92.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 276.9%, from -$52.00M to $92.00M. Over 3 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -37.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $268.00M | $351.00M | $160.00M | -$136.00M | -$151.00M | -$48.00M | $133.00M | $320.00M | $547.00M | -$19.00M | $155.00M | $242.00M | $229.00M | -$52.00M | $146.00M | $32.00M | $130.00M | $92.00M |
| QoQ Change | — | +31.0% | -54.4% | -185.0% | -11.0% | +68.2% | +377.1% | +140.6% | +70.9% | -103.5% | +915.8% | +56.1% | -5.4% | -122.7% | +380.8% | -78.1% | +306.3% | -29.2% |
| YoY Change | — | — | — | — | -156.3% | +64.7% | +188.1% | — | — | +60.4% | +16.5% | -24.4% | -58.1% | -173.7% | -5.8% | -86.8% | -43.2% | +276.9% |